Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17–30 months

Peer Review reports

Original Submission
19 Nov 2022	Submitted	Original manuscript
25 Nov 2022	Reviewed	Reviewer Report
4 Dec 2022	Reviewed	Reviewer Report - Christian Lucas
6 Dec 2022	Author responded	Author comments - Martin H Ruttledge
Resubmission - Version 2
6 Dec 2022	Submitted	Manuscript version 2
Publishing
17 Dec 2022	Editorially accepted
16 Jan 2023	Article published	10.1186/s10194-022-01536-3

Back to article page